QPX7831 clinical trials
Also written QPX7831.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How each study uses QPX7831 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses QPX7831 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy ParticipantsCompletedPhase 1Qpex Biopharma, Inc.NCT06079775Written as Xeruborbactam Oral ProdrugHow we know
- PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal ImpairmentCompletedPhase 1Qpex Biopharma, Inc.NCT06157242Written as Xeruborbactam Oral ProdrugHow we know
- Phase 1 Oral QPX7831 SAD and MAD in Healthy AdultsCompletedPhase 1Qpex Biopharma, Inc.NCT04578873Written as QPX7831How we know